Clinical trial · Interventional
Development of an Intervention to Enhance Cancer Pain Management
NCT03752268CI-TRIAL-00106613active not recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This research study is being done to understand how patients with chronic cancer pain take their long-acting opioid medications, and to develop an intervention to enhance cancer pain management.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Other Cancer | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Enhancing Cancer Pain Management | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- NO_INTERVENTION
- label
- Enhancing Cancer Pain Management Part 1
- description
- * Will collect information from participants via self-report assessment at two time points: at baseline (i.e. study enrollment) and approximately 8 weeks post-baseline * Will then use MEMS to monitor LA opioid intake over approximately 8 weeks * A subset of enrolled participants (n=20) will be invited to participate in an optional one-time qualitative exit interview with a study staff member trained in conducting qualitative interviews
- type
- EXPERIMENTAL
- label
- Enhancing Cancer Pain Management Part 2
- description
- * Enhancing Cancer Pain Management will consist of 3 individual manualized sessions * The 3 individual manualized sessions will be conducted (approximately 20 minutes each), led by a nurse practitioner, to provide sufficient dose for change in adherence behaviors. * Learning and practicing skills for managing cancer-related pain and adhering to prescribed LA opioid regimens. * Study staff will provide participants with MEMS caps and bottles at time of enrollment, to monitor LA opioid intake over approximately 14 weeks.
- interventionNames
- Behavioral: Enhancing Cancer Pain Management
Primary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 21 Years
Show eligibility criteria text
Inclusion Criteria: * Age 21 or older * Currently prescribed a long-acting (LA) opioid for nociceptive cancer pain (extended release oxycodone, extended-release morphine, transdermal fentanyl patches, methadone tablets) * Ability to comprehend study materials in English * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 * In charge of administering own pain medications * Part 2 study only: within 4 months of current prescription of LA opioid for nociceptive cancer pain Exclusion Criteria: * Impaired cognition, active substance disorder, or other active, unstable mental health disorder * Current long-acting opioid treatment for pre-existing condition * Part 2 study only: Prior enrollment in the Part 1 study\*\*
References
Publications (0)
Data not yet available
No reference posted for this study.